Lenvatinib versus sorafenib as second-line therapy following progression on atezolizumab–bevacizumab in patients with unresectable hepatocellular carcinoma: a multicenter retrospec... by Jaekyung Cheon, Shigeo Shimose, Hyung-Don Kim, Takashi Niizeki, Min-Hee Ryu, Tomotake Shirono, Baek-Yeol Ryoo, Hideki Iwamoto, Changhoon Yoo

Get full text

Serum 25‐Hydroxyvitamin D Levels and Survival Outcomes in Advanced Biliary Tract Cancer: Results From the NIFTY Trial by So Heun Lee, Jaekyung Cheon, Ilhwan Kim, Kyu‐pyo Kim, Baek‐Yeol Ryoo, Jae Ho Jeong, Myoung Joo Kang, Byung Woog Kang, Hyewon Ryu, Ji Sung Lee, Changhoon Yoo

Get full text

Second-Line Irinotecan, Leucovorin, and 5-Fluorouracil for Gastric Cancer Patients after Failed Docetaxel and S-1 by Joo Young Jung, Min-Hee Ryu, Baek-Yeol Ryoo, Boram Han, Ji Woong Cho, Man Sup Lim, Hyun Lim, Ho Suk Kang, Min-Jeong Kim, Hong Il Ha, Hunho Song, Jung Han Kim, Hyeong Su Kim, Yoon-Koo Kang, Dae Young Zang

Get full text

Efficacy and safety of lenvatinib in patients with recurrent hepatocellular carcinoma after liver transplantation by Kyunghye Bang, Andrea Casadei‐Gardini, Changhoon Yoo, Massimo Iavarone, Min‐Hee Ryu, Sook Ryun Park, Hyung‐Don Kim, Young‐In Yoon, Dong‐Hwan Jung, Gil‐Chun Park, Chul‐Soo Ahn, Deok‐Bog Moon, Shin Hwang, Ki‐Hun Kim, Gi‐Won Song, Chiara Mazzarelli, Eleonora Alimenti, Stephen L. Chan, Massimo De Giorgio, Baek‐Yeol Ryoo, Sung‐Gyu Lee

Get full text